Evidence map›Paper›PMID 28988016›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2017

Characterisation of the immune-related transcriptome in resected biliary tract cancers.

Michele Ghidini, Luciano Cascione, Pietro Carotenuto, Andrea Lampis, Francesco Trevisani, Maria Chiara Previdi, Jens C Hahne, Ian Said-Huntingford, Maya Raj, Alessandro Zerbi and 10 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Molecular Biomarkers in Cholangiocarcinoma: Focus on Bile.Current topics in medicinal chemistry · 2024
    Review
  5. Review
  6. Immunobiology of cholangiocarcinoma.Journal of hepatology · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Michele GhidiniThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK; Humanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni, 113, Rozzano, Milan, 20089, Italy; ASST Hospital of Cremona, Viale Concordia, 1, Cremona, 26100, Italy.
Luciano CascioneInstitute of Oncology Research, Via Vela 6, Bellinzona, 6500, Switzerland.
Pietro CarotenutoThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK.
Andrea LampisThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK.
Francesco TrevisaniThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK; San Raffaele Scientific Institute, Via Olgettina, Milan, 20132, Italy.
Maria Chiara PrevidiThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK.
Jens C HahneThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK.
Ian Said-HuntingfordThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK.
Maya RajThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK.
Alessandro ZerbiHumanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni, 113, Rozzano, Milan, 20089, Italy; Humanitas University, Via Manzoni, 113, Rozzano, Milan, 20089, Italy.
Claudia MescoliUniversity of Padua, Via Gabelli 61, Padova, 35100, Italy.
Umberto CilloUniversity of Padua, Via Gabelli 61, Padova, 35100, Italy.
Massimo RuggeUniversity of Padua, Via Gabelli 61, Padova, 35100, Italy.
Massimo RoncalliHumanitas University, Via Manzoni, 113, Rozzano, Milan, 20089, Italy.
Guido TorzilliHumanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni, 113, Rozzano, Milan, 20089, Italy; Humanitas University, Via Manzoni, 113, Rozzano, Milan, 20089, Italy.
Lorenza RimassaHumanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni, 113, Rozzano, Milan, 20089, Italy.
Armando SantoroHumanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni, 113, Rozzano, Milan, 20089, Italy; Humanitas University, Via Manzoni, 113, Rozzano, Milan, 20089, Italy.
Nicola ValeriThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK; The Royal Marsden NHS Foundation Trust, London and Surrey, Downs Road, SM2 5PT, UK.
Matteo FassanUniversity of Padua, Via Gabelli 61, Padova, 35100, Italy.
Chiara BraconiThe Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK; The Royal Marsden NHS Foundation Trust, London and Surrey, Downs Road, SM2 5PT, UK. Electronic address: chiara.braconi@icr.ac.uk.
Institute of Cancer Research · GBHumanitas University · ITUniversity of Padua · ITRoyal Marsden NHS Foundation Trust · GBInstitute of Oncology Research · CH

Funding

Cancer Research UK 18052
6 · The paper itself

Abstract

Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune Profiling Panel was used to assess the expression of 770 immune-related transcripts in the tumour tissues (TTs) and matched adjacent tissues (ATs) of resected BTCs. Cox regression analysis and Kaplan-Meier methods were used to correlate findings with relapse-free survival (RFS). The first analysis in the TT and AT of an exploratory set (n = 22) showed deregulation of 39 transcripts associated with T-cell activation. Risk of recurrence was associated with a greater number of genes deregulated in AT in comparison to TT. Analysis in the whole set (n = 53) showed a correlation between AT cytotoxic T-lymphocyte antigen-4 (CTLA4) expression and RFS, which maintained statistical significance at multivariate analysis. CTLA4 expression correlated with forkhead box P3 (FOXP3) expression, suggesting enrichment in T regulatory cells. CTLA4 is known to act by binding to the cluster of differentiation 80 (CD80). No association was seen between AT CD80 expression and RFS. However, CD80 expression differentiated prognosis in patients who received adjuvant chemotherapy. We showed that the immunomodulatory transcriptome is deregulated in resected BTCs. Our study includes a small number of patients and does not enable to draw definitive conclusions; however, it provides useful insights into potential transcripts that may deserve further investigation in larger cohorts of patients. TRANSCRIPT PROFILING: Nanostring data have been submitted to GEO repository: GSE90698 and GSE90699.

Indexed as

TranscriptomeTumor MicroenvironmentAdultAgedB7-1 AntigenBiliary Tract NeoplasmsBiliary Tract Surgical ProceduresBiomarkers, TumorCTLA-4 AntigenDisease-Free SurvivalFemaleForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansItalyB7-1 AntigenBiomarkers, TumorCTLA-4 AntigenCTLA4 protein, humanForkhead Transcription FactorsFOXP3 protein, humanAdjuvantCD80CholangiocarcinomaCTLA4Treg

Identifiers

PMID28988016
PMCPMC5699791
OpenAlexW2762253923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.